on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Presents LUMEVOQ® at NANOS 2025
GenSight Biologics, a key player in gene therapies for neurodegenerative diseases, is presenting data on its lead product, LUMEVOQ®, in Tucson at the 51st Annual NANOS Meeting. This year's focus is on Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disorder leading to rapid vision loss.
Experts will share their findings on various aspects of LUMEVOQ®, including predictors of treatment response and comparisons with other treatments such as idebenone. The conference, which takes place from March 15 to 20, 2025, will also highlight the long-term effectiveness of bilateral treatments.
It is also an opportunity to discuss real-life experiences and the impact of these advances on the daily lives of patients with this disease.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news